Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) shares reached a new 52-week high on Tuesday . The stock traded as high as $12.62 and last traded at $12.27, with a volume of 32949 shares changing hands. The stock had previously closed at $12.51.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on the stock. Morgan Stanley reaffirmed an "overweight" rating on shares of Fresenius SE & Co. KGaA in a research note on Thursday, May 15th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating on shares of Fresenius SE & Co. KGaA in a research note on Monday, February 3rd.
View Our Latest Research Report on FSNUY
Fresenius SE & Co. KGaA Trading Down 1.9%
The company has a quick ratio of 1.05, a current ratio of 1.36 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $27.41 billion, a P/E ratio of 64.58 and a beta of 0.78. The firm's 50-day moving average price is $11.34 and its 200 day moving average price is $10.09.
Fresenius SE & Co. KGaA (OTCMKTS:FSNUY - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.23 earnings per share for the quarter, topping analysts' consensus estimates of $0.22 by $0.01. The business had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.41 billion. As a group, equities research analysts predict that Fresenius SE & Co. KGaA will post 0.79 earnings per share for the current year.
Fresenius SE & Co. KGaA Increases Dividend
The firm also recently announced a dividend, which will be paid on Wednesday, June 4th. Investors of record on Wednesday, May 28th will be issued a $0.1827 dividend. This represents a dividend yield of 1.48%. The ex-dividend date is Tuesday, May 27th. This is a positive change from Fresenius SE & Co. KGaA's previous dividend of $0.17. Fresenius SE & Co. KGaA's dividend payout ratio is currently 94.74%.
About Fresenius SE & Co. KGaA
(
Get Free Report)
Fresenius SE & Co KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fresenius SE & Co. KGaA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. KGaA wasn't on the list.
While Fresenius SE & Co. KGaA currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
